Mersana Therapeutics has developed innovative antibody-drug conjugate (ADC) platforms, specifically the Dolasynthen and Immunosynthen technologies, aimed at enhancing cancer treatment efficacy and safety. The Dolasynthen platform allows for the creation of site-specific, homogeneous ADCs with a customizable drug-to-antibody ratio (DAR) ranging from 2 to 18+. This flexibility enables the optimization of ADCs for specific targets, which is crucial since different cancer types may require different therapeutic approaches. The platform also emphasizes the importance of precise bioconjugation, ensuring consistent drug delivery to targeted cancer cells, and features a proprietary payload that enhances the therapeutic index while allowing for a controlled bystander effect, which can further impact the tumor microenvironment.

In addition to Dolasynthen, Mersana's Immunosynthen platform focuses on immunostimulatory ADCs that leverage the immune system to combat cancer. This multi-faceted approach includes targeting specific tumor antigens, such as B7-H4 and novel HER2 epitopes, to address various solid tumors with high unmet medical needs. The combination of cytotoxic and immunostimulatory payloads in Mersana's ADCs aims to improve both safety and efficacy compared to first-generation technologies. Through these advanced platforms, Mersana is building a robust pipeline of first-in-class ADC candidates designed to significantly enhance the lives of patients battling cancer.

United States

At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. 

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). 

Cancer

Immune System Diseases

Mersana Therapeutics

Non-small cell lung carcinoma

Solid tumor/s

XMT-1592 is an ADC created using our proprietary Dolasynthen platform – a customizable and homogeneous platform designed to precisely optimize an ADC for a given target, drug-to-antibody ratio (DAR) and antibody. XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock payload with controlled bystander effect as XMT-1536, with the additional features of site-specific bioconjugation, precise DAR and homogeneous DAR distribution.&nbsp;In preclinical studies, Dolasynthen ADCs show enhanced pharmacokinetics, higher tumor exposure, and greater efficacy compared to Dolaflexin ADCs.

XMT-2056 (HER2 ADC)

Breast cancer

Endometrial cancer

Ovarian cancer

XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and our clinically validated DolaLock microtubule inhibitor payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors.

Emiltatug Ledadotin (Emi-Le; XMT-1660)

XMT-1592 (NaPi2b antigen)

XMT-1536, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver an average of 10-12 DolaLock payload molecules per antibody.&nbsp;The NaPi2b antigen is broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma.&nbsp;XMT-1536 is in a Phase 1 proof-of-concept clinical trial in patients with ovarian cancer and NSCLC adenocarcinoma.

Mersana Therapeutics

Company Details